Anticancer agent 45 

Anticancer agent 46 (compound 2b) is a potent and selective anticancer agent. Anticancer agent 46 shows cytotoxicity activity in cancer cells. Anticancer agent 46 induces apoptosis. Anticancer agent 46 shows low toxicity towards activated lymphocytes of human blood^[1].

Anticancer agent 46 (compound 2b) (0-100 µM; 72 h) shows antitumor activity with GI₅₀S of 1.30, 7.25, 4.00, 6.20, 8.00, 6.13, 4.52, 5.65, 1.10, >100, 73.62 µM for Jurkat, A549, MCF-7, MDA-MB-231, KB3-1, HeLa, HCT-116, HCT-116 p53-/-, U251, SK-OV-3, HaCaT cells, respectively^[1].
Anticancer agent 46 (1.5 µM; 24 h) induces apoptosis by increases the expression of caspase 3, Bax and decreases the amount of anti-apoptotic Bcl-2 protein^[1].
Anticancer agent 46 (compound 2b) (0-2 µM; 24, 48 h) shows low toxicity towards normal human keratinocytes of HaCaT line and mitogen-activated lymphocytes of peripheral blood of healthy human donor^[1].
Anticancer agent 46 dose not induce significant DNA damage and changes in morphology of mitogen-activated lymphocytes of peripheral blood of healthy donor^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

515.95

C₂₂H₁₄ClN₃O₆S₂

2770943-87-6

O=C(C(N(C/1=O)C(SC1=C/C(Cl)=C/C2=CC=C([N+]([O-])=O)C=C2)=S)C3)N(C4=CC=C(O)C=C4)C3=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Finiuk N, et al. Novel hybrid pyrrolidinedione-thiazolidinones as potential anticancer agents: Synthesis and biological evaluation. Eur J Med Chem. 2022 May 2;238:114422.  [Content Brief]